| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/04/2002 | WO2001050848A3 Clonal propagation of primate offspring by embryo splitting |
| 04/04/2002 | WO2001049298A3 Novel therapeutic use of enoxaparin |
| 04/04/2002 | WO2001048231A3 Method of achieving persistent transgene expression |
| 04/04/2002 | WO2001047898A3 Substituted piperazine derivatives and their use as inhibitors of the microsomal triglyceride transfer protein (mtp) |
| 04/04/2002 | WO2001047507A3 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 04/04/2002 | WO2001044197A3 2-phenyl-quinoline derivatives and their use as contracting agent for smooth muscles |
| 04/04/2002 | US20020040154 Reacting arylhydroxy compound and an epoxy compound to form an epoxy-aryl ether; reacting epoxy-aryl ether with active methylene compound to form a lactone; reducing to provide hydroxy-substituted tetrahydrofuran |
| 04/04/2002 | US20020040146 Useful as inhibitors of metalloproteases, e.g. zinc proteases, and which are effective in therapy of disease states associated with vasoconstriction |
| 04/04/2002 | US20020040135 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them |
| 04/04/2002 | US20020040064 Administering agent that inhibits the contraction or migration of smooth muscle cells; sustained dosage; biological stents |
| 04/04/2002 | US20020040058 Oral administration of a preparation having a) long chain polyunsaturated fatty acids, and b) specified phospholipids, and c) compounds that factor in methionine metabolism, such as folate, B vitamins, magnesium and zinc |
| 04/04/2002 | US20020040053 Administering 2,5,7,8-tetramethyl-2-( beta-carboxyethyl)-6-hydroxychromane, or 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychromane; treating arteriosclerosis, disease caused by oxidated low density lipoprotein |
| 04/04/2002 | US20020040052 By administering a poyalkoxyflavonoid having a specific structure, especially nobiletin or tangeretin; plant extract from citrus family |
| 04/04/2002 | US20020040048 (2S,4R)-4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carboxylic acid N'-isobutyl-N'-(4-methyl-benzenesulfonyl)-hydrazide, for example; inhibitors of metalloproteases, e.g. zinc proteases; vasodilators |
| 04/04/2002 | US20020040045 Method of treating isolated systolic hypertension |
| 04/04/2002 | US20020040025 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 04/04/2002 | US20020040024 A phenoxy substituted piperidine derivative, useful for treating or preventing histamine H3 receptor activity |
| 04/04/2002 | US20020040022 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection |
| 04/04/2002 | US20020040017 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 04/04/2002 | US20020040013 Novel therapeutic use of low molecular weight heparins |
| 04/04/2002 | US20020040007 Novel macrolide antibiotics |
| 04/04/2002 | US20020040002 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| 04/04/2002 | US20020039774 Anticholesterol agents |
| 04/04/2002 | US20020039736 Reacting aliphatic aminonitrile with water in presence of solid alumina catalyst to form lactam |
| 04/04/2002 | US20020039724 Neural progenitor cell populations |
| 04/04/2002 | US20020039574 Delivery of therapeutic gene products by intestinal cell expression |
| 04/04/2002 | US20020039560 Drug delivery |
| 04/04/2002 | DE10046838A1 Verwendung von Myxoxanthophyll und/oder Echinenon zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten, durch oxidative Prozesse bedingten oder begünstigten körperlichen Zuständen Use of Myxoxanthophyll and / or echinenone for prophylactic and / or therapeutic treatment of unwanted situations due to oxidative processes beneficiary physical conditions |
| 04/04/2002 | DE10045845A1 Xenon als Arzneimittel Xenon as medicinal |
| 04/04/2002 | DE10044792A1 Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung Substituted Phenylcyclohexancarbonsäureamide and their use |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2426117A1 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| 04/04/2002 | CA2424021A1 Catecholamine compositions and uses thereof |
| 04/04/2002 | CA2423955A1 Kini-3 motor protein and methods for its use |
| 04/04/2002 | CA2423919A1 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | CA2423889A1 Methods and compositions for screening modulators of lipid kinases |
| 04/04/2002 | CA2423704A1 G-protein coupled receptors |
| 04/04/2002 | CA2423668A1 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 04/04/2002 | CA2423474A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | CA2423464A1 Hydroxy acid integrin antagonists |
| 04/04/2002 | CA2423434A1 Lactone integrin antagonists |
| 04/04/2002 | CA2423424A1 Secreted proteins |
| 04/04/2002 | CA2423313A1 Methods of treating inflammatory and immune reactions and compositions therefor |
| 04/04/2002 | CA2423305A1 Compounds useful in the treatment of inflammatory diseases |
| 04/04/2002 | CA2423251A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 04/04/2002 | CA2423141A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 04/04/2002 | CA2422873A1 Piperazin-2-one amides as inhibitors of factor xa |
| 04/04/2002 | CA2421209A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases |
| 04/04/2002 | CA2420960A1 Potassium channel interactors and uses therefor |
| 04/04/2002 | CA2420851A1 .alpha.-substituted .beta.-aminoethyl phosphonates |
| 04/04/2002 | CA2420672A1 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/04/2002 | CA2420577A1 Peptide-based compounds |
| 04/04/2002 | CA2420475A1 Ige receptor antagonists |
| 04/04/2002 | CA2420045A1 Melanocortin receptor ligands |
| 04/03/2002 | EP1193268A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
| 04/03/2002 | EP1193267A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases |
| 04/03/2002 | EP1193256A1 Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins |
| 04/03/2002 | EP1192951A2 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound |
| 04/03/2002 | EP1192949A1 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 04/03/2002 | EP1192279A2 Diagnostics and therapeutics for cardiovascular disorders |
| 04/03/2002 | EP1192278A1 48 human secreted proteins |
| 04/03/2002 | EP1192277A2 Diagnostics and therapeutics for restenosis |
| 04/03/2002 | EP1192261A1 22025, a novel human cyclic nucleotide phosphodiesterase |
| 04/03/2002 | EP1192258A2 Human poly(adp-ribose) polymerase 2 materials and methods |
| 04/03/2002 | EP1192257A2 Human regulators of intracellular phosphorylation |
| 04/03/2002 | EP1192252A2 Secreted protein zacrp4 |
| 04/03/2002 | EP1192250A2 Human rna metabolism proteins (rmep) |
| 04/03/2002 | EP1192249A1 47 human secreted proteins |
| 04/03/2002 | EP1192247A1 Sphingosine kinase enzyme |
| 04/03/2002 | EP1192187A1 Heparin compositions that inhibit clot associated coagulation factors |
| 04/03/2002 | EP1192170A1 Propargyl phenyl ether a2a receptor agonists |
| 04/03/2002 | EP1192169A2 C-pyrazole a2a receptor agonists |
| 04/03/2002 | EP1192163A1 DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 04/03/2002 | EP1192161A2 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands |
| 04/03/2002 | EP1192158A2 Substituted 8-phenylxanthines useful as antagonists of a 2b? adenosine receptors |
| 04/03/2002 | EP1192157A1 Bispidine compounds useful in the treatment of cardiac arrhythmias |
| 04/03/2002 | EP1192156A1 Bispidine compounds useful in the treatment of cardiac arrhythmias |
| 04/03/2002 | EP1192155A1 New bispidine compounds useful in the treatment of cardiac arrhythmias |
| 04/03/2002 | EP1192154A1 Bispidine compounds useful in the treatment of cardiac arrhythmias |
| 04/03/2002 | EP1192152A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 04/03/2002 | EP1192150A1 New pharmaceutically active compounds |
| 04/03/2002 | EP1192148A1 Thiochroman derivatives resisting neurological disorders |
| 04/03/2002 | EP1192146A1 Chroman derivatives resisting neurological disorders |
| 04/03/2002 | EP1192141A1 1,4-diazacycloheptane derivatives as neuroprotective agents |
| 04/03/2002 | EP1192137A1 COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY |
| 04/03/2002 | EP1192134A2 Processes for the preparation of (r)-g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol |
| 04/03/2002 | EP1192133A1 N-cyclopentyl modulators of chemokine receptor activity |
| 04/03/2002 | EP1192132A2 Serine protease inhibitors |
| 04/03/2002 | EP1192122A1 Benzene derivatives, preparation method and pharmaceutical compositions containing same |
| 04/03/2002 | EP1191947A1 Methods for treating avm' using radioactive compositions |
| 04/03/2002 | EP1191941A1 A method for the prophylaxis and/or treatment of medical disorders |
| 04/03/2002 | EP1191940A1 Tumor necrosis factor receptor 5 |
| 04/03/2002 | EP1191935A1 A method for the treatment or prevention of coronary graft vasospasm |
| 04/03/2002 | EP1191934A1 Il-8 receptor antagonists |
| 04/03/2002 | EP1191931A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
| 04/03/2002 | EP1191845A1 Prevention of brain damage in stroke |
| 04/03/2002 | EP1052973B1 Transmucosal formulations of levosimendan |
| 04/03/2002 | EP1007512B1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors |
| 04/03/2002 | EP0931087B1 Novel pyranoside derivatives |
| 04/03/2002 | EP0775199B1 Superoxide dismutase-4 |